• Stanford School of Medicine
  •  use browser back button to return
  • Surgical Pathology Criteria
    http://surgpathcriteria.stanford.edu/

    Apocrine Carcinoma of the Breast

    Definition

    • Breast carcinoma with abundant eosinophilic cytoplasm, large round nuclei and sharp cell borders

    Alternate / Historical Names

    • Carcinoma with apocrine metaplasia
    • Sweat gland carcinoma of the breast

    Diagnostic Criteria

    • Clinically significant criteria have not generally been agreed upon
      • Most describe some degree of abundant eosinophilic cytoplasm, sharp cell borders, round nuclei and prominent nucleoli
      • Some simply refer to GCDFP15 positive carcinomas as apocrine
    • Japaze 2005 has proposed the following criteria:
      • At least 75% of microscopic fields must demonstrate the following features:
        • Large cells with abundant eosinophilic cytoplasm
          • Usually granular
        • Nucleus to cytoplasm ratio of 1:2 or more
        • Nuclei round, large and vesicular
          • May be pleomorphic
        • Sharply defined cell borders
      • Minor (non-mandatory) criteria
        • Prominent nucleoli in >50% of fields
        • Apical cytoplasmic snouts into lumenal spaces
      • Japaze 2005 reported significantly improved survival when apocrine carcinomas were defined as above

    Richard L Kempson MD
    Robert V Rouse MD
    Department of Pathology
    Stanford University School of Medicine
    Stanford CA 94305-5342

    Original posting:: May 1, 2006
    Updates: February 9, 2009

    Supplemental studies

    Immunohistology and Histochemistry

    • GCDFP15 reactivity is generally considered to be strong and universal in apocrine lesions
      • Such reactivitiy is taken by some to define apocrine differentiation
      • Note that the criteria employed by Japaze et al. are not based on immunologic reactivity
    • PASd may show granular cytoplasmic positivity

    • Demonstration of myoepithelial cells can confirm the in situ nature of a process while their absence supports invasion
      • We prefer to use both p63 and calponin on problematic cases
      • A variety of markers have been used for myoepithelial cells:
      Marker Sensitivity Specificity
      Calponin Excellent Very good
      p63 Excellent Excellent
      Smooth muscle myosin heavy chain Good Excellent
      CD10 (CALLA) Good Good
      High molecular weight cytokeratin Very good Poor
      Maspin Good Poor
      S100 Good Very poor
      Actin Good Very poor
    • E-cadherin appears to be a sensitive marker of ductal differentiation vs lobular differentiation; its utility in borderline lesions is currently uncertain

    • Immunologic markers useful for identification of breast carcinoma
    • GCDFP15 (BRST2) Estrogen Receptor Progesterone Receptor PAX8
      Infiltrating ductal carcinoma 60-70% 75% 50-60% 0%
      Infiltrating lobular carcinoma 60-70% >95% 80% 0%
      Lung adenocarcinoma 0-1% <5% <5% 0%
      Ovarian adenocarcinoma 1-5% 50-100% 40-90% 90-100%
      Endometrioid adenocarcinoma negative 70% 70%  
      GI adenocarcinoma negative <5% 1-10% 0%
      Pancreatic adenocarcinoma negative negative 0-5% 0%
      Cholangiocarcinoma negative negative 30%  
      Thyroid carcinoma negative 20% 30% 100%
    • Sweat gland and salivary gland neoplasms may also be positive for GCDFP15, ER and PR
    • Prostatic adenocarcinoma may be positive for GCDFP15

    • CK7 and CK20 have not been tested on a series of apocrine carcinomas, thus their utility is unknown

    Prognostic/Therapeutic Markers

    • Estrogen receptor (ER) and progesterone receptor (PR) are important markers for directing therapy and determining prognosis
      • Current consensus is that any level of positivity should be reported as positive
    • Her2neu status can be determined by either immunohistology or by FISH
      • The other technique can be used for borderline case

    Genetic analysis

    • Her2neu status can be determined by either immunohistology or by FISH
      • The other technique can be used for borderline cases

    Differential Diagnosis

     

    Apocrine Carcinoma Secretory Carcinoma
    Large vesicular nuclei with prominent nucleoli Low grade nuclei with inconspicuous nucleoli
    Cytoplasm granular, eosinophilic Cytoplasm granular or clear and vacuolated
    PASd may show granular cytoplasmic staining PASd shows abundant cytoplasmic mucin
    No predilection for young patients Most cases <30 years
    Many show aggressive behavior Excellent prognosis

     

    Histiocytoid Carcinoma Apocrine Carcinoma of the Breast
    Amphophilic to weakly eosinophilic cytoplasm Intensely eosinophlic cytoplasm
    Cytoplasm vacuolated, occasionally granular Cytoplasm granular
    Indistince cytoplasmic borders Sharp cytoplasmic borders
    Small nuclei and nucleoli Large vesicular nuclei with prominent nucleoli
    Appears to have more aggressive behavior than usual carcinoma Appears to have better behavior than usual carcinoma in some series
    Some consider histiocytoid carcinoma to be a variant of breast carcinomas with apocrine features

     

    Lipid Rich Carcinoma Apocrine Carcinoma
    Cytoplasm clear to multivacuolated Cytoplasm nearly uniformly granular
    Cytoplasm at most focally eosinophilic Cytoplasm nearly uniformly eosinophilic
    Scant PASd positivity in cells Frequently PASd positive
    Fat stains positive Fat stains negative
    GCDFP15 variable/weak GCDFP15 strong positive

     

    Apocrine Carcinoma Oncocytic Carcinoma
    GCDFP15 strong diffuse positive GCDFP15 negative
    Anti-mitochondrial stain weak, focal Anti-mitochondrial antibody stain strong, diffuse
    Indistinguishable on H&E stain; clinical significance of difference unknown

    Clinical

    • Most studies have shown no clear difference in behavior from usual invasive breast carcinoma
    • One study, strictly applying the criteria outlined here, found a significantly better prognosis for apocrine carcinoma compared to infiltrating ductal carcinoma NOS (Japaze 2005)
      • Overall six year survival 72% vs. 52%
      • Grade 3 overall six year survival 83% vs. 51%
    • Another study, not using these criteria, found decreased lymph node metastases and decreased lymphatic invasion (Tanaka 2008)
      • Follow up was too short to evaluate survival

    Grading / Staging / Report

    Grading

    • The study of Japaze et al. found a better prognosis for apocrine carcinoma compared to grade matched infiltrating carcinoma NOS, raising the possibility that the grading scheme should be modified for apocrine lesions
      • Note that the grading scheme for DCIS is modified for apocrine DCIS

    • Bloom-Scarff-Richardson grading scheme is most widely used
    • Total score and each of the three components should be reported
    • Based on invasive area only
    Tubule formation Score
    >75% tubules 1
    10-75% tubules 2
    <10% tubules 3

     

    Nuclear pleomorphism (most anaplastic area) Score
    Small, regular, uniform nuclei, uniform chromatin 1
    Moderate varibility in size and shape, vesicular, with visible nucleoli 2
    Marked variation, vesicular, often with multiple nucleoli 3

     

    Mitotic figure count per 10 40x fields (depends on area of field, see key below) Score
    0.096 mm2 0.12 mm2 0.16 mm2 0.27 mm2 0.31 mm2
    0-3 0-4 0-5 0-9 0-11 1
    4-7 5-8 6-10 10-19 12-22 2
    >7 >8 >10 >19 >22 3
    • Olympus BX50, BX40 or BH2 or AO or Nikon with 15x eyepiece: 0.096 mm2
    • AO with 10x eyepiece: 0.12 mm2
    • Nikon or Olympus with 10x eyepiece: 0.16 mm2
    • Leitz Ortholux: 0.27 mm2
    • Leitz Diaplan: 0.31 mm2
    • Mitotic count figures based on original data presented for Leitz Ortholux by Elston and Ellis 1991, with modifications based on pubished and measured areas of view
    • Evaluate regions of most active growth, usually in cellular areas at periphery
    • We employ strict criteria for identification of mitotic figures
    Sum of above three components Overall grade
    3-5 points Grade I (well differentiated)
    6-7 points Grade II (moderately differentiated)
    8-9 points Grade III (poorly differentiated)

    Staging

    • TNM staging is the most widely used scheme for breast carcinomas but is not universally employed
    • Critical staging criteria for regional lymph nodes
      • Isolated tumor cell clusters
        • Usually identified by immunohistochemistry
          • Term also applies if cells identified by close examination of H&E stain
        • No cluster may be greater than 0.2 mm
        • Multiple such clusters may be present in the same or other nodes
      • Micrometastasis
          • Greater than 0.2 mm, none greater than 2.0 mm
      • Metastasis
        • At least one carcinoma focus over 2.0 mm
          • If one node qualifies as >2.0 mm, count all other nodes even with smaller foci as involved
        • Critical numbers of involved nodes: 1-3, 4-9 and 10 and over
      • Note extranodal extension

    Report

    • Excisions: the following are important elements that must be addressed in the report for infiltrative breast carcinomas
      • Grade
        • Total score and individual components
      • Size of neoplasm
        • Give 3 dimensions or greatest dimension
        • Critical cutoffs occur at 0.5 cm and at 2 cm
      • Margins of resection
        • Measure and report the actual distance of both invasive and in situ carcinoma
      • Angiolymphatic invasion
        • Indicate if confined to tumor mass, outside tumor mass or in dermis
      • (Extensive DCIS is not currently felt to be a significant predictor of behavior)
      • Results of special studies performed for diagnosis
      • Results of prognostic special studies performed
        • ER, PR, Proliferation marker, Her2neu
        • If studies were performed on a prior specimen, refer to that report and give results
    • Needle or core biopsies
      • Provisional grade may be given but may defer to excision for definitive grade
      • Presence of absence of angiolymphatic invasion
      • Results of special studies performed for diagnosis
      • Results of prognostic special studies if performed
        • ER, PR, Proliferation marker, Her2neu
        • State if studies are deferred for a later excision specimen
    • Regional lymph nodes
      • Report findings as described above

    Lists

    Infiltrating Breast Carcinomas

    Bibliography

    • Japaze H, Emina J, Diaz C, Schwam RJ, Gercovich N, Demonty G, Morgenfeld E, Rivarola E, Gil Deza E, Gercovich FG. 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast. 2005 Feb;14(1):3-10.
    • Page DL. Apocrine carcinomas of the breast. Breast. 2005 Feb;14(1):1-2.
    • Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403-10.
    • Tanaka K, Imoto S, Wada N, Sakemura N, Hasebe K. Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. Breast J. 2008 Mar-Apr;14(2):164-8.
    Printed from Surgical Pathology Criteria: http://surgpathcriteria.stanford.edu/
    © 2005  Stanford University School of Medicine